![Cureus | Analysis of Overall Survival in Patients With Multiple Primary Malignancies: A Single-center Experience | Article Cureus | Analysis of Overall Survival in Patients With Multiple Primary Malignancies: A Single-center Experience | Article](https://assets.cureus.com/uploads/figure/file/56884/lightbox_96799eb01b4f11e9836e8ffceb76b5f5-Figure-1.png)
Cureus | Analysis of Overall Survival in Patients With Multiple Primary Malignancies: A Single-center Experience | Article
![Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41391-020-00316-x/MediaObjects/41391_2020_316_Fig1_HTML.png)
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
![Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab](https://www.mdpi.com/cancers/cancers-12-03021/article_deploy/html/images/cancers-12-03021-g001-550.jpg)
Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection | PLOS ONE
![Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC - Journal of Thoracic Oncology Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC - Journal of Thoracic Oncology](https://www.jto.org/cms/asset/5912d2b9-3a18-45ba-8b3a-d2435566258a/gr1.jpg)
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC - Journal of Thoracic Oncology
![Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data](https://www.archivesofmedicalscience.com/f/pictures/99749_28bf0.jpg)
Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data
![Overall survival plot. Kaplan–Meier curve is shown for overall survival... | Download Scientific Diagram Overall survival plot. Kaplan–Meier curve is shown for overall survival... | Download Scientific Diagram](https://www.researchgate.net/publication/356259194/figure/fig2/AS:1091002400022593@1637126650745/Overall-survival-plot-Kaplan-Meier-curve-is-shown-for-overall-survival-in-patients-with.png)
Overall survival plot. Kaplan–Meier curve is shown for overall survival... | Download Scientific Diagram
![Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-018-0061-6/MediaObjects/41416_2018_61_Fig1_HTML.jpg)
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer
![562 Overall survival rates and progression free survival in IDS vs PDS in advanced ovarian cancer patients in the university hospitals of Leicester | International Journal of Gynecologic Cancer 562 Overall survival rates and progression free survival in IDS vs PDS in advanced ovarian cancer patients in the university hospitals of Leicester | International Journal of Gynecologic Cancer](https://ijgc.bmj.com/content/ijgc/31/Suppl_3/A251.2/F1.large.jpg)
562 Overall survival rates and progression free survival in IDS vs PDS in advanced ovarian cancer patients in the university hospitals of Leicester | International Journal of Gynecologic Cancer
![Overall survival. The Kaplan-Meier graph shows overall survival of the... | Download Scientific Diagram Overall survival. The Kaplan-Meier graph shows overall survival of the... | Download Scientific Diagram](https://www.researchgate.net/publication/312548097/figure/fig1/AS:616359859863564@1523963050372/Overall-survival-The-Kaplan-Meier-graph-shows-overall-survival-of-the-entire-patient.png)
Overall survival. The Kaplan-Meier graph shows overall survival of the... | Download Scientific Diagram
![Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet](https://www.thelancet.com/cms/asset/480689df-d7d2-4224-9823-835cc1312b92/gr1.jpg)
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet
![Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - Journal of Hepatology Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - Journal of Hepatology](https://www.journal-of-hepatology.eu/cms/asset/9618d6ae-163e-494b-8a58-f82c2164f797/ga1.jpg)